Hijacking a Cancer Cell's Own Metabolism to Target Elusive Cancers

by Dr. Trupti Shirole on  February 21, 2017 at 12:24 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Triple-negative breast cancer has low survival rates. There are no targeted therapeutics for this deadly breast cancer so far, because it doesn't have any of the receptors on it that are normally targeted.
 Hijacking a Cancer Cell's Own Metabolism to Target Elusive Cancers
Hijacking a Cancer Cell's Own Metabolism to Target Elusive Cancers

Targeted cancer therapies rely on specific markers on the surface of cancer cells. Scientists can design antibodies that seek out those markers and deliver therapeutic or imaging agents. However, some cancers are not eligible for this kind of treatment because they lack surface markers to target.

By hijacking a cancer cell's own metabolism, researchers have found a way to tag and target elusive cancers with small-molecule sugars. This opens treatment pathways for cancers that are not responsive to conventional targeted antibodies, such as triple-negative breast cancer.

Led by Jianjun Cheng, a Hans Thurnauer Professor of Materials Science and Engineering at the University of Illinois, researchers at Illinois and collaborators in China published their findings in the journal Nature Chemical Biology.

The researchers found a way to mark the cells using a class of small-molecule sugars called azides. Once metabolized in the cell, they are expressed on the surface, and can be targeted by a molecule called DBCO.

"It's very much like a key in a lock. They are very specific to each other. DBCO and azide react with each other with high specificity. We call it click chemistry," Cheng said. "The key question is, how do you put azide just on the tumor?"

To make sure the azide would only be expressed on the surface of cancer cells, the researchers added a protective group to the azide sugar that could only be removed by tumor-specific enzymes. In normal tissues, the azide sugar simply travels through. In tumor cells, it is completely metabolized and expressed on the cell surface, creating specific targets for DBCO to deliver a cargo of cancer-treating drugs or imaging agents.

The researchers tested the azide-based targeting system in mice with tumors from colon cancer, triple-negative breast cancer and metastatic breast cancer.

"We found the tumors had very strong signals compared with other tissues," Cheng said. "For the first time, we labeled and targeted tumors with small molecule sugars in vivo, and we used the cancer cell's own internal mechanisms to do it."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Amyotrophic Lateral Sclerosis (ALS) Resting Metabolic Rate Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Galactosemia Top 10 Ways to Speed up Your Metabolism For Weight Loss 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive